Clinical trials
Recurrent or Metastatic Nasopharyngeal Carcinoma clinical trials
Below are recruiting recurrent or metastatic nasopharyngeal carcinoma clinical trials, each written for real people, not researchers. We’re tracking 2,322 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06650579RecruitingPhase 3
Heart safety study of relugolix vs leuprolide for prostate cancer
This trial compares two hormone therapy combinations for men with prostate cancer that hasn't spread. The goal is to see if a newer oral medication (Relugolix) plus abiraterone works better than the standard injectable therapy (Lupron) plus abiraterone, while also checking heart safety.
Atlanta, GeorgiaAges 18 years+ - NCT06654011RecruitingPhase 2
A study testing a new combination for rare cervical cancer
This trial tests whether adding the drug IN10018 to a standard chemotherapy and immunotherapy combination can help treat a rare type of cervical cancer called gastric-type adenocarcinoma that has spread or come back. The goal is to see if this combination improves outcomes for patients who have already had at least one round of chemotherapy.
Wuhan, HubeiAges 18–75 - NCT06616584RecruitingPhase 2/Phase 3
Cemiplimab plus standard care for advanced lung cancer after prior treatments
This trial tests whether adding the immunotherapy drug cemiplimab to standard treatment can help people with advanced lung cancer that has already progressed after both platinum chemo and a prior immunotherapy. It is designed for those who responded to their first immunotherapy for at least 12 weeks before the cancer started growing again.
Daphne, AlabamaAges 18 years+ - NCT06359847RecruitingPhase 2
ST-1898 for advanced thyroid cancer that no longer responds to iodine therapy
This trial tests an experimental drug called ST-1898 for people with advanced thyroid cancer that has stopped responding to radioactive iodine treatment and has progressed after at least one targeted therapy. It aims to see if ST-1898 can shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06537193Recruiting
Shorter MRI vs CT scan to check for liver cancer return
This trial compares a shorter MRI using a special dye to a CT scan for detecting liver cancer recurrence in people who have been cancer-free for at least two years after surgery or local treatment.
Seoul, Songpa-gu , 88, Olympic-ro 43-gilAges 20 years+ - NCT06518564RecruitingPhase 2
Avelumab and M1774 for ARID1A-mutated endometrial cancer
This trial tests a combination of two drugs, avelumab (an immunotherapy) and M1774, in people with a specific type of endometrial cancer that has an ARID1A gene mutation. The goal is to see if this combination can shrink tumors or slow cancer growth.
Boston, MassachusettsAges 18 years+ - NCT06478693RecruitingPhase 1
Study of MT-303 for advanced liver cancer
This study tests a new drug called MT-303 for people with advanced liver cancer (HCC) or other cancers that produce a protein called GPC3. The drug is designed to target and attack the cancer cells. The trial is in an early phase, so it is looking at safety and how well the drug works.
Sydney, New South WalesAges 18 years+ - NCT06469281RecruitingPhase 1
A new immune cell therapy for recurring ovarian cancer
This early-phase trial tests a new immune cell therapy called 27T51, which targets a protein called MUC16 found on ovarian cancer cells. The study is for people with recurrent or treatment-resistant ovarian, primary peritoneal, or fallopian tube cancer to see if the therapy is safe and works when given alone or with other treatments.
Boston, MassachusettsAges 18 years+ - NCT06471205RecruitingPhase 2
Study of BL-B01D1 plus immunotherapy for advanced triple-negative breast cancer
This study tests a new drug combination (BL-B01D1 plus an immunotherapy) for people with advanced triple-negative breast cancer who have not had prior treatment for their advanced disease. The goal is to see if the combination works better at shrinking or controlling the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06467799RecruitingPhase 2
New drug combo before and after surgery for high-risk liver cancer
This trial tests giving a liver-directed chemotherapy (HAIC) plus an immunotherapy (PD-1) before surgery, followed by more immunotherapy after surgery, for people with a specific type of liver cancer that has a high chance of coming back. The goal is to see if this approach can reduce the risk of recurrence.
Guangzhou, GuangdongAges 18–75 - NCT06348719Recruiting
Robot vs. standard laparoscopy for early endometrial cancer
This trial compares two types of minimally invasive surgery (robot-assisted vs. conventional laparoscopy) for removing the uterus in people with early-stage, low- to intermediate-risk endometrial cancer. The goal is to see which approach offers the best value and outcomes.
LilleAges 18 years+ - NCT03758976Recruiting
Study of scans in advanced breast cancer recurrence
This study looks at people with advanced breast cancer to better understand recurrence by using information from recent scans. It may help researchers improve how advanced disease is assessed and followed over time.
LundAges 18 years+ - NCT06420219Recruiting
New head and neck cancer study for untreated patients
This study is looking at newly diagnosed head and neck cancer before any treatment begins. It will analyze your cancer's genes and other markers to understand how it develops and grows, which may help improve future care.
Los Angeles, CaliforniaAges 18 years+ - NCT06241612RecruitingPhase 3
Personalized neck radiation for nasopharyngeal cancer
This trial tests whether giving radiation only to the specific lymph nodes that need it works as well as standard radiation for people with nasopharyngeal cancer. It aims to reduce side effects while still controlling the cancer.
Guangzhou, GuangdongAges 18–70 - NCT05582122RecruitingPhase 2
Tracking HPV16 DNA in blood to spot cancer coming back
This study checks whether a blood test for HPV16 DNA can predict when HPV-related throat cancer comes back after treatment. It may help improve follow-up care by catching recurrence earlier.
Saint-Denis, La RéunionAges 18 years+ - NCT06279364RecruitingPhase 3
Testing SKB264 vs standard chemo for advanced triple-negative breast cancer
This trial tests a new drug called SKB264 against standard chemotherapy options for people with advanced triple-negative breast cancer who have not yet received chemotherapy for their advanced disease. The goal is to see if SKB264 works better than the usual treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05803018RecruitingPhase 1/Phase 2
Study drug for advanced gynecologic cancer that stopped working
This Phase 1/2 study tests BL-B01D1 in people with recurrent or metastatic gynecologic cancers (such as ovarian, uterine, or cervical cancer) when standard treatments have failed or aren’t options. It focuses on how well the drug works and whether it can be given safely.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05990803RecruitingPhase 2
Testing new drugs for advanced cervical and gynecologic cancers
This trial tests a new drug called BL-B01D1, alone or combined with another drug (SI-B003), for people with cervical or other gynecologic cancers that have spread or come back after standard treatments. The goal is to see if this treatment can help when other options have stopped working.
Beijing, Beijing MunicipalityAges 18–75 - NCT06042894RecruitingPhase 2
Study of two drugs for advanced HER2-negative breast cancer
This trial tests two experimental drugs, SI-B003 and BL-B01D1 plus SI-B003, for people with HER2-negative breast cancer that has spread or cannot be removed by surgery. It is for those who have tried standard treatments or cannot have them.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06131450RecruitingPhase 1/Phase 2
Study of BL-M07D1 for HER2-positive gynecologic cancers
This trial tests a new drug called BL-M07D1 for women with HER2-positive or low-HER2 gynecologic cancers that have returned or spread. The drug is designed to target and kill cancer cells that make HER2, and may help when other treatments have stopped working.
Beijing, Beijing MunicipalityAges 18–75 - NCT06266338RecruitingPhase 2
Pembrolizumab and lenvatinib for recurrent or metastatic cervical cancer
This study tests a combination of two drugs, pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy), for people with cervical cancer that has come back or spread. The goal is to see if this drug combination can shrink tumors or slow the cancer's growth.
Dallas, TexasAges 18 years+ - NCT06241781RecruitingPhase 2
Immune cells from your tumor for cervical cancer
This trial tests a new treatment using your own immune cells (called tumor-infiltrating lymphocytes) that are grown in a lab and given back to you. It is for people with cervical cancer that has come back or spread and hasn't been stopped by other treatments.
Beijing, Beijing MunicipalityAges 18–70 - NCT06223542RecruitingPhase 1
TAK-243 for advanced cancers that haven't responded to other treatments
This trial tests a new drug called TAK-243 for people with advanced cancers (solid tumors or lymphomas) that have not responded to other treatments. It aims to see if the drug is safe and how well it works.
Bethesda, MarylandAges 18 years+ - NCT06210490RecruitingPhase 2
Antibody-drug combo with radiation for HER2+ UTUC after surgery
This trial tests a combination of an antibody-drug conjugate (Disitamab Vedotin) plus radiation therapy after surgery to prevent upper tract urothelial cancer from coming back. It is for patients with HER2-positive tumors and high-risk features who cannot receive cisplatin chemo.
Beijing, Beijing MunicipalityAges 18 years+
Hear when a new Recurrent or Metastatic Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic nasopharyngeal carcinoma?
- Yes. Clin2 currently lists 2,322 recruiting recurrent or metastatic nasopharyngeal carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic nasopharyngeal carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic nasopharyngeal carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Recurrent Nasopharyngeal Carcinoma
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Metastatic Nasopharyngeal Carcinoma
- Metastatic Nasopharyngeal Squamous Cell Carcinoma
- Recurrent Nasopharyngeal Squamous Cell Carcinoma
- Nasopharyngeal Carcinoma
- Metastatic Renal Cell Carcinoma
- Nasopharyngeal Carcinoma (NPC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.